BACKGROUND: Hereditary ovarian cancers (HOC) represent about 23% of ovarian cancer (OC) cases: they are mostfrequently related to germline mutations in the BRCA genes.OBJECTIVE: We aimed to compare CA125/HE4 serum levels and Computed Tomography (CT) features at time of ovariancancer (OC) diagnosis in two populations: BRCA mutant and BRCA wild-type (WT) OC, and to investigate the relationshipbetween this laboratory and radiological biomarker and BRCA mutation status.METHODS: This retrospective study included 60 newly diagnosed OC patients with FIGO stage IIIC-IV disease, tested forBRCA1/2 germline mutation status of which preoperative CT scan and serum tumor marker assay were available.RESULTS: The median level of CA125 (708 U/mL) was significantly higher (p < 0.002) in BRCA1/2 mutated patients thanin WT patients (176 U/mL), whereas the median level of HE4 (492 pmol/L) was significantly higher (p < 0.002) in WT thanin BRCA-mutated patients (252 pmol/L). BRCA mutation carriers showed a higher incidence of bilateral ovarian masses(p = 0.0303) characterized by solid structures (p < 0.00001), higher peritoneal tumor load, macronodular implants >2 cm(p = 0.000099), increased frequency of lymphadenopathies (p = 0.019), and metastasis (p = 0.052) compared to patients withBRCA WT.CONCLUSIONS: Tumor markers and CT patterns may help in identifying BRCA mutation status in OC directing patients towards a personalized treatment.

CT imaging phenotypes linked to CA125 and HE4 biomarkers are highly predictive in discriminating between hereditary and sporadic ovarian cancer patients / Manganaro, Lucia; Celli, Veronica; Viggiani, Valentina; Berardelli, Elena; Granato, Teresa; Tartaglione, Sara; Farina, Antonella; Catalano, Carlo; Angeloni, Antonio; Anastasi, Emanuela. - In: TUMOR BIOLOGY. - ISSN 1010-4283. - 44:1(2022), pp. 171-185. [10.3233/TUB-211557]

CT imaging phenotypes linked to CA125 and HE4 biomarkers are highly predictive in discriminating between hereditary and sporadic ovarian cancer patients

Manganaro, Lucia
Primo
;
Celli, Veronica
Secondo
;
Viggiani, Valentina;Berardelli, Elena;Tartaglione, Sara;Farina, Antonella;Catalano, Carlo;Angeloni, Antonio
Penultimo
;
Anastasi, Emanuela
Ultimo
2022

Abstract

BACKGROUND: Hereditary ovarian cancers (HOC) represent about 23% of ovarian cancer (OC) cases: they are mostfrequently related to germline mutations in the BRCA genes.OBJECTIVE: We aimed to compare CA125/HE4 serum levels and Computed Tomography (CT) features at time of ovariancancer (OC) diagnosis in two populations: BRCA mutant and BRCA wild-type (WT) OC, and to investigate the relationshipbetween this laboratory and radiological biomarker and BRCA mutation status.METHODS: This retrospective study included 60 newly diagnosed OC patients with FIGO stage IIIC-IV disease, tested forBRCA1/2 germline mutation status of which preoperative CT scan and serum tumor marker assay were available.RESULTS: The median level of CA125 (708 U/mL) was significantly higher (p < 0.002) in BRCA1/2 mutated patients thanin WT patients (176 U/mL), whereas the median level of HE4 (492 pmol/L) was significantly higher (p < 0.002) in WT thanin BRCA-mutated patients (252 pmol/L). BRCA mutation carriers showed a higher incidence of bilateral ovarian masses(p = 0.0303) characterized by solid structures (p < 0.00001), higher peritoneal tumor load, macronodular implants >2 cm(p = 0.000099), increased frequency of lymphadenopathies (p = 0.019), and metastasis (p = 0.052) compared to patients withBRCA WT.CONCLUSIONS: Tumor markers and CT patterns may help in identifying BRCA mutation status in OC directing patients towards a personalized treatment.
2022
ovarian cancer; BRCA; computed tomography; HE4-CA125
01 Pubblicazione su rivista::01a Articolo in rivista
CT imaging phenotypes linked to CA125 and HE4 biomarkers are highly predictive in discriminating between hereditary and sporadic ovarian cancer patients / Manganaro, Lucia; Celli, Veronica; Viggiani, Valentina; Berardelli, Elena; Granato, Teresa; Tartaglione, Sara; Farina, Antonella; Catalano, Carlo; Angeloni, Antonio; Anastasi, Emanuela. - In: TUMOR BIOLOGY. - ISSN 1010-4283. - 44:1(2022), pp. 171-185. [10.3233/TUB-211557]
File allegati a questo prodotto
File Dimensione Formato  
Manganaro_CT imaging phenotypes_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 529.67 kB
Formato Adobe PDF
529.67 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1653345
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact